Literature DB >> 16197617

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Elisabeth I Heath1, Melvin Gaskins, Henry C Pitot, Roberto Pili, Winston Tan, Robert Marschke, Glenn Liu, David Hillman, Fazlul Sarkar, Shijie Sheng, Charles Erlichman, Percy Ivy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16197617     DOI： 10.3816/cgc.2005.n.024

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN： 1540-0352


× No keyword cloud information.
  24 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 3.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

Review 4.  Hsp90: a drug target?

Authors:  Jeffrey M Holzbeierlein; Andrew Windsperger; George Vielhauer
Journal:  Curr Oncol Rep       Date:  2010-03       Impact factor: 5.075

Review 5.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

6.  Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Authors:  H Carl Le; Mihaela Lupu; Khushali Kotedia; Neal Rosen; David Solit; Jason A Koutcher
Journal:  Magn Reson Med       Date:  2009-11       Impact factor: 4.668

7.  Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.

Authors:  Preeti Putcha; Karin M Danzer; Lisa R Kranich; Anisa Scott; Melanie Silinski; Sarah Mabbett; Carol D Hicks; James M Veal; Paul M Steed; Bradley T Hyman; Pamela J McLean
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

Review 8.  [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Authors:  L Rinnab; A Hessenauer; S V Schütz; E Schmid; R Küfer; F Finter; R E Hautmann; K D Spindler; M V Cronauer
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

9.  Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.

Authors:  He Wang; Mingjie Lu; Mengqian Yao; Wei Zhu
Journal:  Mol Clin Oncol       Date:  2016-07-19

10.  P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

Authors:  Andrea K McCollum; Cynthia J TenEyck; Bridget Stensgard; Bruce W Morlan; Karla V Ballman; Robert B Jenkins; David O Toft; Charles Erlichman
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.